This open-label, randomized, Phase III study compared the efficacy and tolerability of and compliance with NuvaRing, a combined contraceptive vaginal ring releasing 15 microg of ethinylestradiol (EE) and 120 microg of etonogestrel daily, with those of and with a combined oral contraceptive (COC) containing 150 microg of levonorgestrel (LNG) and 30 microg of EE. Subjects received NuvaRing or a COC for 13 cycles (3 weeks of ring/pill treatment followed by a 1-week ring-/pill-free period). A total of 1030 subjects (NuvaRing, n=512; COC, n=518) was randomized and started treatment (intent-to-treat [ITT] population). The percentage of women in the ITT population who completed the trial was 70.9% for the NuvaRing group and 71.2% for the COC group. Five in-treatment pregnancies occurred in each group, giving Pearl indices of 1.23 for NuvaRing and 1.19 for the COC. Compliance with both treatments was excellent and both were well tolerated. In conclusion, NuvaRing has comparable efficacy and tolerability with a COC containing 150 microg of LNG and 30 microg of EE and does not require daily dosing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2004.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reproduction control in a feral feline population using an anti-GnRH vaccine.
Theriogenology
January 2025
Instituto de Investigaciones en Reproducción Animal, FCV, UNLP, Calle 60 y 118, La Plata, B1900AVW, Buenos Aires, Argentina; Universidad del Chaco Austral, Argentina. Electronic address:
This study aimed to evaluate the use of the Improvac® vaccine to avoid heat and pregnancies in queens and fertility in males during the breeding season. Twenty-eight intact animals were divided into treated males (G1, n = 7), treated females (G2, n = 18), and untreated males (G3, n = 3) that were untamed and could not be captured for immunization. In cats from the G1 group, the testicular volume (337.
View Article and Find Full Text PDFRemoval of an incarcerated intrauterine device reaching the serosal surface of the uterus by hysteroscopy alone: a case report.
Front Med (Lausanne)
January 2025
Department of Gynecology and Obstetrics, International Peace Maternity and Child Health Hospital Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Embryo Original Diseases, Shanghai Municipal Key Clinical Specialty, Shanghai, China.
Background: An intrauterine device (IUD) is a widely used long-term contraceptive device for family planning. However, the IUD can lead to various complications. Severe complications and remedial measures caused by IUDs have been reported in the literature; however, detailed surgical approaches for safely removing the IUD within the minimum surgical range have rarely been described especially in postmenopausal women.
View Article and Find Full Text PDFIntroduction: Cervical cancer remains the second most common cancer among women worldwide, with 85% of cases occurring in low-and middle-income countries (LMIC). Women living with HIV (WLWH) are at a particularly high risk of developing for high-grade cervical intraepithelial neoplasia (CIN2/3) and cervical cancer, and the standard surgical treatment is far less effective in this population. Thus, research on medical therapies and combination treatment options remain a priority.
View Article and Find Full Text PDF[Factors influencing pain during intrauterine device insertion].
Gynecol Obstet Fertil Senol
January 2025
Département de Gynécologie et Obstétrique, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Chemin des Bourrely, 13015 Marseille, France.
Objectives: Fear of pain during intrauterine device (IUD) insertion remains a barrier to its adoption. In the absence of consensus on an optimal pharmacological strategy, it is crucial to determine the factors influencing this pain to reassure and improve the patient experience.
Methods: It was a prospective study conducted in Provence-Alpes-Côte d'Azur between August 2023 and 2024, interviewing adult patients and healthcare professionals during consultations for IUD insertion.
Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention.
J Control Release
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA; Magee-Womens Research Institute, Pittsburgh, PA, USA; Department of Obstetrics, Gynecology & Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address:
User adherence contributes to the effectiveness of topical pre-exposure prophylactic products designed to protect against human immunodeficiency virus type 1 (HIV-1) infection. Long-acting approaches that do not require daily or coitally-dependent use could potentially improve user adherence. This study aims to develop a long-acting vaginal film to deliver an integrase inhibitor, MK-2048, for prevention of HIV-1 infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!